A polypeptide having tyrosinase inhibitory activity and its application

By developing polypeptides with tyrosinase inhibitory activity, the problem of inhibiting tyrosinase activity in the prior art has been solved, and the effect of efficient whitening and treatment of diseases related to melanin or catecholamine metabolism is achieved, with safety and wide application prospects.

CN118005729BActive Publication Date: 2024-11-15CHINA AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410216522.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-27
Publication Date
2024-11-15
Estimated Expiration
2044-02-27

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit tyrosinase activity, affecting melanin and catecholamine metabolism, and there are shortcomings in safety, specificity and targeting of polypeptide drugs, which limits the therapeutic effects of whitening chemicals and related diseases.

Method used

A polypeptide with tyrosinase inhibitory activity has been developed, which has good hydrophilicity, long half-life and can be absorbed through the intestinal tract. It inhibits tyrosinase activity through intestinal absorption and expresses the Polypeptides to improve their biological activity and stability.

Benefits of technology

It has achieved efficient inhibition of tyrosinase activity, is safe and has broad application prospects, and is suitable for whitening chemicals and the treatment of diseases related to abnormal metabolism of melanin or catecholamines, significantly improving the effect of tyrosinase inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118005729B_ABST
    Figure CN118005729B_ABST
Patent Text Reader

Abstract

The present invention provides a polypeptide having tyrosinase inhibitory activity and its application, wherein the amino acid sequence of the polypeptide is shown in SEQ ID NO: 1. The polypeptide of the present invention has a strong ability to inhibit tyrosinase activity, has advantages such as good hydrophilicity, long half-life, and can be absorbed through the intestine, and can be used to develop products having tyrosinase inhibitory activity, and has broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a polypeptide with tyrosinase inhibitory activity and application thereof. Background Art

[0002] Melanin is the main factor that determines skin color, and tyrosinase is the key rate-limiting enzyme in the process of melanin production. Therefore, the inhibition rate of tyrosinase activity is a direct indicator for evaluating daily chemical products with whitening effects.

[0003] Tyrosinase is also a key enzyme in the metabolism of melanin and catecholamines. Abnormal tyrosinase activity may cause diseases related to abnormal metabolism of melanin and catecholamines. In recent years, artificially synthesized peptides with biological activity have attracted much attention. Compared with chemical drugs, peptide drugs have the characteristics of small molecular weight, strong specificity, good targeting and high safety.

[0004] Therefore, the research and development of peptides with tyrosinase inhibitory activity is of great significance for the development of daily chemical products with whitening effects and the clinical treatment of diseases related to abnormal melanin and catecholamine metabolism. Summary of the invention

[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides a polypeptide having tyrosinase inhibitory activity and its application. The polypeptide of the present invention has a strong ability to inhibit tyrosinase activity, has advantages such as good hydrophilicity, long half-life, and can be absorbed through the intestine, and can be used to develop products having tyrosinase inhibitory activity, and has broad application prospects.

[0006] Therefore, in the first aspect of the present invention, the present invention provides a polypeptide. According to an embodiment of the present invention, the polypeptide has an amino acid sequence as shown in SEQ ID NO:1.

[0007] HPFLF (SEQ ID NO: 1).

[0008] It should be noted that the amino acid sequences mentioned in the present invention are all shown from N-terminus to C-terminus.

[0009] The polypeptides according to the embodiments of the present invention have strong ability to inhibit tyrosinase activity, and have the advantages of high safety, good hydrophilicity, long half-life, and ability to be absorbed through the intestine, and can be used to develop products with tyrosinase inhibitory activity, with broad application prospects.

[0010] It should be noted that, without substantially affecting the tyrosinase inhibitory activity of the polypeptide of the present invention (retaining at least 90% of the activity), one or more amino acid residues of the polypeptide of the present invention may be replaced by other amino acid residues from the same side chain family, and the functional assay method described herein may be used to test the retained function of the altered polypeptide. Preferably, the number of conservative modifications does not exceed 1 or 2.

[0011] In a second aspect of the present invention, the present invention provides a nucleic acid molecule. According to an embodiment of the present invention, the nucleic acid molecule encodes the aforementioned polypeptide.

[0012] The nucleic acid according to the embodiment of the present invention can encode the aforementioned polypeptide which has strong inhibitory effect on tyrosinase activity and also has the advantages of high safety, long half-life, good hydrophilicity, and ability to be absorbed through the intestine.

[0013] It should be noted that, for the nucleic acid molecules mentioned herein, those skilled in the art will understand that they actually include any one or two of the complementary double strands. For convenience, in this article, although only one strand is provided in most cases, the other strand complementary thereto is actually disclosed. In addition, the molecular sequence in the present invention includes a DNA form or an RNA form, and disclosing one of them means that the other is also disclosed.

[0014] In the third aspect of the present invention, the present invention provides a construct. According to an embodiment of the present invention, the construct comprises the aforementioned nucleic acid molecule. Thus, the constructed construct, such as a vector or a transformant, can effectively express the aforementioned polypeptide.

[0015] According to an embodiment of the present invention, the construct may be a vector or a transformant.

[0016] In this article, the term "vector" generally refers to a nucleic acid molecule that can be inserted into a suitable host and replicates itself, and the inserted nucleic acid molecule is transferred into and / or between host cells. The vector may include a vector that is mainly used to insert DNA or RNA into a cell, a vector that is mainly used to replicate DNA or RNA, and a vector that is mainly used for the expression of transcription and / or translation of DNA or RNA. The vector also includes a vector with a variety of the above functions. The vector can be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. Typically, the vector can produce a desired expression product by cultivating a suitable host cell that contains the vector.

[0017] According to an embodiment of the present invention, the construct (such as a vector or a transformant) may include an optional control sequence, which is operably connected to the nucleic acid molecule. Wherein, the control sequence is one or more control sequences that can direct the expression of the nucleic acid molecule in a host. The construct (such as a vector or a transformant) thus constructed can effectively express the above-mentioned polypeptide.

[0018] When the nucleic acid molecule is connected to the construct (such as a vector or a transformant), such as an expression vector, the nucleic acid molecule can be directly or indirectly connected to the control elements on the expression vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself. The nucleic acid molecule can be operably connected to the control element.

[0019] In some embodiments of the present invention, the vector may refer to a cloning vector or an expression vector, which can be obtained by operably connecting the nucleic acid to a commercially available vector (such as a plasmid or a viral vector). The vector in the present invention is not particularly limited, and commonly used plasmids can be used, such as pSeTag2, PEE14, pMH3, etc.

[0020] In this article, the term "operably linked" refers to connecting the exogenous gene to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, can play their intended functions of regulating the transcription and translation of the exogenous gene. Commonly used vectors may be, for example, viral vectors, plasmids, bacteriophages, etc.

[0021] After the expression vector according to some specific embodiments of the present invention is introduced into a suitable recipient cell, it can effectively express the aforementioned nucleic acid molecule under the mediation of the regulatory system, thereby achieving large-scale in vitro production of the polypeptide encoded by the nucleic acid molecule.

[0022] In some embodiments of the present invention, the vector is a eukaryotic vector or a prokaryotic vector.

[0023] In a fourth aspect of the present invention, the present invention provides a recombinant cell. According to an embodiment of the present invention, the cell carries the aforementioned nucleic acid molecule or the aforementioned construct; or expresses the aforementioned polypeptide. According to an embodiment of the present invention, the cell can efficiently express the aforementioned polypeptide under appropriate conditions, and further, the obtained polypeptide has strong inhibitory tyrosinase activity, and has the advantages of high safety, long half-life, good hydrophilicity, and can be absorbed through the intestine.

[0024] In some embodiments of the present invention, the cell is a prokaryotic cell, a eukaryotic cell or a bacteriophage.

[0025] In some embodiments of the present invention, the prokaryotic cell is Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis.

[0026] In some embodiments of the present invention, the eukaryotic cell is a fungus, an insect cell, a plant cell or a mammalian cell.

[0027] In some embodiments of the present invention, the fungus is Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe or Trichoderma.

[0028] In some embodiments of the present invention, the insect cells are fall armyworm cells; according to an embodiment of the present invention, the plant cells are tobacco plant cells; according to an embodiment of the present invention, the mammalian cells are BHK cells, CHO cells, COS cells, myeloma cells or human embryonic kidney 293 cells; and do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0029] In some embodiments of the invention, the cell is a mammalian cell.

[0030] In some embodiments of the present invention, the cell is a BHK cell, a CHO cell, a COS cell or a NSO cell.

[0031] It should be noted that the "suitable conditions" described in the specification of this application refer to conditions suitable for the expression of the polypeptide described in this application. It is easy for those skilled in the art to understand that the conditions suitable for the polypeptide include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell states, suitable host cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions" are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of the polypeptide according to the specific environment of the laboratory.

[0032] In a fifth aspect of the present invention, the present invention provides a method for improving the tyrosinase inhibitory activity of a sample. According to an embodiment of the present invention, the method comprises: contacting the sample with the aforementioned polypeptide.

[0033] Exemplarily, the sample is a blood sample of a melanoma model animal, a skin cell or skin cell culture, or a skin tissue organoid.

[0034] It should be noted that the term "contact" used in this article should be understood in a broad sense, and can be any method that can cause at least two reactants to undergo a chemical reaction, such as mixing the two reactants under appropriate conditions.

[0035] Those skilled in the art will appreciate that the features and advantages described above for the polypeptide are also applicable to this method and will not be described in detail here.

[0036] In a sixth aspect of the present invention, the present invention provides the use of the aforementioned polypeptide in preparing a product. According to an embodiment of the present invention, the product is used to inhibit tyrosinase activity.

[0037] According to an embodiment of the present invention, the product includes: medicine, cosmetics or a test kit.

[0038] Tyrosinase is a key enzyme in the metabolism of melanin and catecholamines. Therefore, drugs containing the aforementioned polypeptides can be used to treat and / or prevent diseases related to abnormal melanin or catecholamine metabolism.

[0039] According to an embodiment of the present invention, the medicine further includes a pharmaceutical composition, and the pharmaceutical composition includes: the aforementioned polypeptide, or the aforementioned tyrosinase inhibitor.

[0040] According to an embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0041] According to an embodiment of the present invention, the auxiliary material includes at least one of an excipient, a diluent, a stabilizer and a carrier.

[0042] According to an embodiment of the present invention, the medicine is an injection or an ointment.

[0043] According to an embodiment of the present invention, the medicine is an external ointment.

[0044] As used herein, the term "pharmaceutical composition" generally refers to a unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art. All methods include the step of combining the active ingredient with a carrier that constitutes one or more accessory ingredients. Generally, the composition is prepared by uniformly and sufficiently combining the active compound with a liquid carrier, a solid carrier, or both.

[0045] As used herein, the term "pharmaceutically acceptable" ingredients are substances that are suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation, and allergic response), ie, substances with a reasonable benefit / risk ratio.

[0046] In this article, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for a specific target dosage form. Except for any conventional excipient incompatible with the compound of the present invention, such as any adverse biological effect produced or any other component of the pharmaceutically acceptable composition interacting in a harmful manner, their use is also within the scope of the present invention.

[0047] Tyrosinase is a key rate-limiting enzyme in the production of melanin. The content and distribution of melanin determine the color of human skin and hair. Therefore, cosmetics containing the aforementioned polypeptides can inhibit the activity of tyrosinase in the body, reduce the production of melanin, and achieve a whitening effect.

[0048] According to an embodiment of the present invention, the cosmetic further comprises cosmetically acceptable excipients.

[0049] Tyrosinase is an important disease pathology indicator. For example, the tyrosinase content in the peripheral blood of patients with malignant melanoma is related to the disease stage and diagnosis. Therefore, the kit containing the above-mentioned polypeptide can be used for in vitro detection of tyrosinase activity in a sample or for inhibiting tyrosinase activity in a sample.

[0050] According to an embodiment of the present invention, the kit further comprises other reagents for detecting tyrosinase activity or inhibiting tyrosinase.

[0051] According to an embodiment of the present invention, the product may also be a tyrosinase inhibitor.

[0052] According to an embodiment of the present invention, the tyrosinase inhibitor includes: the aforementioned polypeptide.

[0053] In some specific embodiments, the tyrosinase inhibitor further comprises other tyrosinase inhibitors. Exemplarily, other tyrosinase inhibitors include but are not limited to: imatinib, erlotinib, gefitinib, glabridin, coumaric acid, hydroquinone, cinnamic acid, arbutin, raspberry ketone, caffeic acid, kojic acid, O-hydroxybenzaldehyde, m-hydroxybenzaldehyde, p-hydroxybenzaldehyde, O-hydroxybenzoic acid, m-hydroxybenzoic acid, p-hydroxybenzoic acid, resveratrol, oxidized resveratrol.

[0054] Those skilled in the art will appreciate that the features and advantages described above for the polypeptide are also applicable to this application and will not be described in detail here.

[0055] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0057] Figure 1 This is a graph showing the high performance liquid chromatography results of the polypeptide HPFLF in Example 1 of the present invention;

[0058] Figure 2 This is a primary mass spectrum result diagram of the polypeptide HPFLF in Example 1 of the present invention;

[0059] Figure 3 A visualization diagram of the result after the polypeptide HPFLF in Example 1 of the present invention is docked with a tyrosinase crystal;

[0060] Figure 4 This is a graph showing the results of investigating the tyrosinase inhibitory activity of the polypeptide HPFLF in Example 1 of the present invention. DETAILED DESCRIPTION

[0061] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0062] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.

[0063] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0064] Terms and Definitions

[0065] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. The abbreviations for amino acid residues are standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids.

[0066] As used herein, the term "conservatively modified forms of an amino acid sequence" refers to amino acid modifications that do not significantly affect or alter the biological activity of a polypeptide comprising the amino acid sequence, including amino acid substitutions, additions, and deletions. Modifications can be introduced into the polypeptides of the invention by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been identified in the art. These families include amino acids with basic side chains (such as lysine, arginine, histidine), amino acids with acidic side chains (such as aspartic acid, glutamic acid), amino acids with uncharged polar side chains (such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with non-polar side chains (such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with beta-branched side chains (such as threonine, valine, isoleucine), and amino acids with aromatic side chains (such as tyrosine, phenylalanine, tryptophan, histidine).

[0067] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0068] Example 1: Solid-phase chemical synthesis of polypeptide HPFLF and prediction of biological activity

[0069] The chemical synthesis of the peptide HPFLF adopts the peptide Fmoc solid phase synthesis technology, and reverse synthesis is performed from the C-terminus to the N-terminus of the peptide sequence.

[0070] First, the carboxyl group of the first amino acid is covalently linked to the carrier resin, and then the amino group of this amino acid is used as the starting point for the reaction to undergo an acylation reaction with the carboxyl group of the adjacent amino acid to form a peptide bond. Repeat this process until the target peptide is synthesized, remove the Fmoc protecting group and drain the resin. Cut with 6 times the volume of the resin (97.50% TFA + 2.50% H2O), wash the precipitate 3 times with anhydrous ether, and obtain a crude polypeptide.

[0071] The peptide was separated and purified by high performance liquid chromatography to obtain a purity of more than 98.99%. Figure 1 shown.

[0072] The amino acid sequence and molecular weight of the peptide were confirmed by LC-MS / MS. Figure 2 shown.

[0073] The above experimental results show that the polypeptide of the present invention (with an amino acid sequence of HPFLF (SEQ ID NO: 1)) can be obtained by chemical synthesis.

[0074] Furthermore, the biological activity of the peptide was predicted using tools such as the PeptideRanker online system. The specific method is as follows:

[0075] The PeptideRanker online system (http: / / bioware.ucd.ie / ~compass / biowareweb / Server_pages / peptideranker.Php) was used to predict the ability of the peptide HPFLF to produce biological effects or activities on organisms; ToxinPred (https: / / webs.iiitd.edu.in / raghava / toxinpred / index.html) was used to predict water solubility and toxicity; Expasy (https: / / web.expasy.org / protparam / ) was used for isoelectric point and half-life analysis; ad metSAR (http: / / lmmd.ecust.edu.cn / admetsar1 / predict / ) was used to predict human intestinal absorption and carcinogenicity.

[0076] The prediction results of toxicity, carcinogenicity, hydrophilicity, half-life, isoelectric point and intestinal absorption activity of the peptide HPFLF are shown in Table 1.

[0077] Table 1 In vitro function prediction results of peptide HPFLF

[0078]

[0079] Among them, PeptideRanker is an algorithm based on machine learning to predict and rank peptide activity. The higher the prediction value of PeptideRanker, the greater the possibility that the corresponding peptide has biological activity; "+" means it can be absorbed through the intestine, and "-" means it cannot be absorbed through the intestine.

[0080] Furthermore, the inventors used Chimera 1.16 to construct the three-dimensional structure of the peptide HPFLF, and performed molecular docking with tyrosinase obtained from the PDB database (http: / / www.rcsb.org / ) and with water molecules and other ligands removed. It was unexpectedly found that the peptide HPFLF had a good affinity with tyrosinase. The specific process is as follows:

[0081] Molecular docking was performed using AutoDock Vina software, with the docking center coordinates set to (-2.927, 22.019, -32.487) (x, y, z) and the docking box size set to 110 × 100 × 110.

[0082] HPFLF peptide was docked as a ligand onto the tyrosinase crystal structure in PDBQT format. The binding of ligand and receptor was visualized using PyMOL software.

[0083] The visualization results are as follows Figure 3 shown.

[0084] The results showed that the molecular binding energy of the polypeptide with the amino acid sequence of HPFLF was -7.5 kcal / mol, indicating that the polypeptide had a good affinity with tyrosinase.

[0085] Example 2: Investigation of Tyrosinase Inhibitory Activity of Polypeptide HPFLF

[0086] In this example, the tyrosinase inhibitory activity of the solid phase synthesized polypeptide HPFLF in Example 1 was further investigated. The specific method is as follows:

[0087] As shown in Table 2, the corresponding reagents and different volumes of samples to be tested were added to the sample wells of the 96-well ELISA plate corresponding to the experimental groups A, B, C, and D. After the addition of tyrosinase, the ELISA plate was incubated at 37°C for 10 minutes, and then the substrate L-tyrosine solution was added and reacted for 10 minutes, and the absorbance was measured at a wavelength of 475 nm using an ELISA reader.

[0088] The tyrosinase activity inhibition rate was calculated as follows:

[0089]

[0090] Wherein, in formula (1): A represents the absorbance of experimental group A measured at a wavelength of 475 nm; B represents the absorbance of experimental group B measured at a wavelength of 475 nm; C represents the absorbance of experimental group C measured at a wavelength of 475 nm; D represents the absorbance of experimental group D measured at a wavelength of 475 nm.

[0091] Table 2 Tyrosinase inhibition rate reaction system

[0092] Experimental Group PBS (μL) Sample to be tested (μL) Tyrosinase (μL) L-Tyrosine (μL) A 100 0 50 50 B 150 0 50 0 C 50 50 50 50 D 100 50 50 0

[0093] The PBS concentration was 0.1 M (pH 6.5), the protein concentration of the HPFLF polypeptide was 8 mg / mL, the tyrosinase activity was 300 U / mL, and the L-tyrosine concentration was 1.5 mM.

[0094] The results of the investigation of the tyrosinase inhibitory activity of the polypeptide HPFLF in Example 1 are as follows: Figure 4 shown.

[0095] The results showed that the tyrosinase activity inhibition rate of the polypeptide HPFLF was as high as about 91%, and it had significant tyrosinase inhibition activity.

[0096] The above results show that the polypeptide HPFLF has high tyrosinase inhibitory activity, and also has the advantages of good hydrophilicity, long half-life, and ability to be absorbed through the intestine. It can be applied to daily chemicals, biomedicine and other fields to develop drugs, cosmetics or test kits with tyrosinase inhibitory activity, and has broad application prospects.

[0097] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0098] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. Use of a polypeptide in the preparation of cosmetics, kits or tyrosinase inhibitors for inhibiting tyrosinase activity, characterized in that: The amino acid sequence of the polypeptide is shown in SEQ ID NO:1.